Highlights and Lowlights

First shop-in-shop
pharmacy opened in
Switzerland

Growth strategy

Revenue up

11.8%

Refocusing

of Halle facility

with a downside:
40 jobs cut

One year after the ECJ ruling

Double-digit

growth with Rx drugs

in Germany

38.7%

OTC sales growth
in Germany

Further expansion of European market leadership

Acquisitions

of Eurapon and Vitalsana

Successful IPO, raising

215 Mio.

in net proceeds

Discussion
of ban on Rx
mail-order
sales continues

6.5%

sales growth in doctors’
supply business in
Switzerland